| Literature DB >> 28491316 |
Hiroyuki Yamazaki1, Masayuki Kobayashi1, Anamaria Daniela Sarca1, Akifumi Takaori-Kondo1.
Abstract
OBJECTIVES: Pituitary abscess is a rare occurrence among pituitary conditions, but one which carries life-threatening potential. An immunocompromised status is a risk factor for the development of a pituitary abscess; however, literature describes only one case among HIV-infected patients. METHODS ANDEntities:
Keywords: HIV-1; panhypopituitarism; pituitary abscess
Year: 2017 PMID: 28491316 PMCID: PMC5406206 DOI: 10.1177/2050313X17701374
Source DB: PubMed Journal: SAGE Open Med Case Rep ISSN: 2050-313X
Figure 1.(a) Diffuse varicella-like eruption on the ventral and dorsal trunk and extremities. (b) Close observation of the skin lesions highlights a combination of maculopapular rash, vesicles filled with a serous exudate, and erythematous ulcers. These eruptions were accompanied by tenderness.
Endocrinological examination values.
| On admission | Result | Unit | Normal range | Combined pituitary function test | Baseline | 15 min | 30 min | 60 min | 90 min | 120 min |
|---|---|---|---|---|---|---|---|---|---|---|
| Adrenocorticotrophic hormone (ACTH) | <1.0 | pg/mL | 7.2–63.3 | ACTH (pg/mL) | 9.4 | 17.8 | 17.3 | 15.5 | 10 | 7.2 |
| Cortisol | 1.4 | mg/dL | 5–15 | Cortisol (mg/dL) | 2.6 | 2.5 | 3 | 3.5 | 2.8 | 2.2 |
| Thyrotropic-stimulating hormone (TSH) | 0.018 | mIU/mL | 0.5–5.0 | TSH (mIU/mL) | 1.8 | – | 2.1 | 2.2 | 2.3 | 2.3 |
| Free T3 | 1.71 | pg/mL | 2.33–4.00 | LH (mIU/mL) | 1.6 | – | 2.8 | 3 | 2.9 | 2.6 |
| Free T4 | 0.607 | ng/mL | 0.88–1.62 | FSH (mIU/mL) | 1.8 | – | 2.8 | 3 | 2.9 | 2.6 |
| Luteinizing hormone (LH) | <1.0 | mIU/mL | 1.7–8.6 | PRL (ng/mL) | 1.2 | – | 1.8 | 1.7 | 1.4 | 1.4 |
| Follicle-stimulating hormone (FSH) | <1.0 | mIU/mL | 1.5–12.4 | Growth hormone (GH)-stimulation test | Baseline | 15 min | 30 min | 45 min | 60 min | |
| Prolactin (PRL) | <1.0 | ng/mL | 3.6–16.3 | GH (ng/mL) | 0.14 | 1.24 | 1.26 | 0.91 | 0.6 | |
| Somatomedin C (IGF-1) | 12 | ng/mL | 41–272 | Hypertonic saline test | Baseline | 30 min | 60 min | 90 min | 120 min | |
| Testosterone | <2.5 | ng/dL | 131–871 | Serum osmolality (mOsm/kg) | 284 | 294 | 299 | 303 | 305 | |
| Free testosterone | <0.4 | pg/mL | 7.7–21.6 | ADH (pg/mL) | <0.8 | <0.8 | <0.8 | <0.8 | 0.9 | |
| Antidiuretic hormone (ADH) | <1.2 | pg/mL | <3.6 |
Figure 2.(a) Axial T1-weighted image showing a hypointense lesion in the pituitary gland surrounded by a slightly hyperintense rim (arrowhead). (b) Axial T2-weighted image depicting sphenoid sinus mucosa thickening and a hyperintense lesion in the mastoid cell (solid arrow). (c) Sagittal and (d) coronal T1-weighted gadolinium-enhanced images showing a ring-enhancing intrasellar lesion with fluid intensity in its inner part. The pituitary stalk is also enhanced. (e) Diffusion-weighted imaging (DWI) indicating a high-intensity mass in the pituitary fossa. (f) The intrasellar lesion demonstrated restricted diffusion on the apparent diffusion coefficient (ADC) image (open arrow).
Figure 3.Post-treatment MRIs. (a) Sagittal and (b) coronal enhanced T1-weighted scans showing disappearance of cystic lesion and improvement of pituitary gland and stalk enhancement.